Valeant

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Valeant's Japan sales performance.

Daily Brief: Andrew Witty's replacement on Accelerated Access initiative, Blincyto gains full EU approval and more

Valeant shares tumble after FDA rejection. A rejection by the US regulator for Valeant’s plaque psoriasis treatment. ... Valeant said in a statement that the FDA had not specified any clinical efficacy or safety shortcomings in its Complete Response

UK, Germany back routine use of J&J’s Tremfya

Add in additional IL-17 inhibitors for Eli Lilly and Valeant and the market for biologics for psoriasis is looking increasingly crowded, and a lot will depend on which of the

Daily Brief

Looking to distance itself from toxic past, Valeant to rebrand as Bausch Health. ... Valeant’s years of buccaneering mergers and acquisitions, suspect business practices and allegations of fraud have left it saddled with debt and a pariah-like status

Sun Pharma passes milestone with novel psoriasis drug approval

IL-23-selective follow-up Tremfya (guselkumab) as well as three IL-17 inhibitors - Novartis’ Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) and Valeant Pharma’s Siliq (brodalumab).

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 (Next 4)

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology

Featured jobs

Market Access Consultant - Greater Manchester: Negotiable

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Medical Writer - Creative and Scientific Projects: DOE

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Manager: Negotiable

Graduate Scientific Editor: DOE

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Associate Scientific Director: Salary TBC

Healthcare PR Director: £100, 000 – £120, 000 benefits

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Account Director or Senior Account Director: Salary TBC

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Medical Writer: Salary is DOE

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Training Manager - Surrey: Competitive Salary &Bonus

Healthcare PR Senior Account Manager: Salary TBC

Account Director, Healthcare Advertising Agency: Salary TBC

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....